Manhattan Pharmaceuticals Inc.
48 Wall Street
Suite 1100
New York,
NY 10005
United States - Map
Phone: 212-582-3950
Fax: 212-582-3957
Web Site: http://www.manhattanpharma.com
| Manhattan Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of pharmaceutical therapies in the United States. Its product candidates under development include Hedrin, a novel, non-insecticide treatment for pediculosis; and Topical PTH (1-34) for the treatment of psoriasis. Manhattan Pharmaceuticals has a joint venture agreement with Nordic Biotech Advisors ApS to develop and commercialize Hedrin. The company was founded in 2001 and is based in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Douglas Abel , 47
Chairman and Consultant |
N/A
| N/A | Mr. Michael G. McGuinness , 55
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer and Sec. |
$
263.00K | N/A | Dr. Mary C. Spellman M.D.,
Head of Dermatology & Drug Devel. and Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
